Publications in collaboration with researchers from Universidad de Navarra (10)

2022

  1. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group

    Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10

  2. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

2020

  1. miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma

    PloS one, Vol. 15, Núm. 2, pp. e0229075

2019

  1. Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study

    Medical Oncology, Vol. 36, Núm. 3

  2. CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402

  3. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

2018

  1. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97